Education
About Us
Working with TipRanks
Follow Us
Quest Diagnostics (DGX)
NYSE:DGX
DGX Stock Chart & Stats
$177.74
-$0.03(-0.02%)
At close: 4:00 PM EST
$177.74
-$0.03(-0.02%)
Day’s Range― - ―
52-Week Range$148.70 - $197.55
Previous CloseN/A
Volume143.08K
Average Volume (3M)836.51K
Market Cap
$19.77B
Enterprise Value$27.60B
Total Cash (Recent Filing)$432.00M
Total Debt (Recent Filing)$6.38B
Price to Earnings (P/E)20.5
Beta0.17
Next Earnings
Feb 10, 2026EPS Estimate
2.36Next Dividend Ex-DateN/A
Dividend Yield1.8%
Share Statistics
EPS (TTM)2.60
Shares Outstanding111,242,360
10 Day Avg. Volume664,763
30 Day Avg. Volume836,514
Financial Highlights & Ratios
PEG Ratio6.95
Price to Book (P/B)2.47
Price to Sales (P/S)1.70
P/FCF Ratio18.42
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue2.54
Enterprise Value/Gross Profit7.64
Enterprise Value/Ebitda12.91
Forecast
1Y Price Target
$203.75Price Target Upside14.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consumer And PartnershipsStrength in the consumer direct-to-consumer segment and new partnerships with leading consumer health companies are expanding the addressable market and improving revenue mix.
Earnings And GuidanceQuarterly revenue and EPS beats, coupled with raised guidance, increase confidence in the company’s growth trajectory and support a potential valuation re-rating.
Utilization And Margin ExpansionHeightened utilization, rising tests per requisition, and stable unit pricing support the potential for margin expansion as mix shifts toward higher-value services.
Bears Say
Investor Sentiment And Sector RotationShare performance remains exposed to investor rotation into other areas of healthcare, which can pressure the stock despite solid underlying results.
Regulatory And Reimbursement RiskUncertainty around payment policy changes such as PAMA creates reimbursement risk that could weigh on revenue visibility and cash flow predictability.
Rising Employee Benefits CostsElevated employee health-care expenses are compressing margins and could limit near-term operating leverage and profit improvement.
Quest Diagnostics News
DGX FAQ
What was Quest Diagnostics’s price range in the past 12 months?
Quest Diagnostics lowest stock price was $148.70 and its highest was $197.55 in the past 12 months.
What is Quest Diagnostics’s market cap?
Quest Diagnostics’s market cap is $19.77B.
When is Quest Diagnostics’s upcoming earnings report date?
Quest Diagnostics’s upcoming earnings report date is Feb 10, 2026 which is in 28 days.
How were Quest Diagnostics’s earnings last quarter?
Quest Diagnostics released its earnings results on Oct 21, 2025. The company reported $2.6 earnings per share for the quarter, beating the consensus estimate of $2.503 by $0.097.
Is Quest Diagnostics overvalued?
According to Wall Street analysts Quest Diagnostics’s price is currently Undervalued.
Does Quest Diagnostics pay dividends?
Quest Diagnostics pays a Quarterly dividend of $0.8 which represents an annual dividend yield of 1.8%. See more information on Quest Diagnostics dividends here
What is Quest Diagnostics’s EPS estimate?
Quest Diagnostics’s EPS estimate is 2.36.
How many shares outstanding does Quest Diagnostics have?
Quest Diagnostics has 111,242,360 shares outstanding.
What happened to Quest Diagnostics’s price movement after its last earnings report?
Quest Diagnostics reported an EPS of $2.6 in its last earnings report, beating expectations of $2.503. Following the earnings report the stock price went down -3.03%.
Which hedge fund is a major shareholder of Quest Diagnostics?
Currently, no hedge funds are holding shares in DGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quest Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$203.75 (14.63% Upside)
$203.75 (14.63% Upside)
Blogger Sentiment
Bullish
DGX Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 867.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $510.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.57%
12-Months-Change
Fundamentals
Return on Equity
13.69%
Trailing 12-Months
Asset Growth
0.63%
Trailing 12-Months
Company Description
Quest Diagnostics
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
DGX Company Deck
DGX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong performance in revenue growth, successful collaborations, and advances in diagnostics. However, the potential impact of PAMA reforms and higher operational costs present challenges.View all DGX earnings summariesDGX Revenue Breakdown
97.39% Diagnostic Information Services
2.61% All other operating segments
DGX Stock 12 Month Forecast
Average Price Target
$203.75
▲(14.63% Upside)
Technical Analysis
Ownership Overview
0.42% Insiders
32.53% Mutual Funds
15.55% Other Institutional Investors
23.76% Public Companies and
Individual Investors